A synergistic effect of Ambroxol and Beta-Glucosylceramide in alleviating immune-mediated hepatitis: A novel immunomodulatory non-immunosuppressive formulation for treatment of immune-mediated disorders - 18/11/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Ambroxol hydrochloride is used in respiratory diseases as a broncholytic therapy. |
• | Beta-Glucosylceramide (GC) is a glycosphingolipid that exerts an immune protective effect. |
• | Coadministration of Ambroxol and GC significantly alleviated immune-mediated liver damage. |
• | A synergistic effect on suppression of intrahepatic CD8+CD25+ was shown. |
• | Synergism was documented for an increase in the CD4/CD8 lymphocyte ratio. |
Abstract |
Background |
Ambroxol hydrochloride is being used in respiratory diseases as a broncholytic therapy. Beta-Glucosylceramide (GC) is a naturally occurring glycosphingolipid that exerts an immune protective effect. The aim of the present study was to determine the synergistic immunomodulatory effect between these two compounds.
Methods |
Immune-mediated hepatitis was induced in the mice by administration of Con A. Mice were treated with either Ambroxol or GC alone or with the combination of both. Mice were followed for their effect on the liver injury, cytokine profile, and the immune system.
Results |
Coadministration of Ambroxol and GC significantly alleviated the liver injury induced by ConA, as demonstrated by the decreased liver enzymes. The combined treatment had a statistically significant synergistic effect on the suppression of intrahepatic CD8+CD25+, an increase in the CD4/CD8 lymphocyte ratio and in the CD8+ intrahepatic lymphocyte trapping, as well as on change of serum in the IL4 levels. The beneficial effect was associated with the promotion of regulatory T lymphocytes subsets, and with a trend for a pro-inflammatory to an anti-inflammatory cytokine shift.
Conclusions |
Coadministration of Ambroxol with GC exerted a synergistic immunoprotective effect in a model of immune-mediated acute liver damage. Considering the high safety profile of both agents, the combination may become a novel immunomodulatory non-immunosuppressive therapeutic agent.
Significance statement |
Coadministration of Ambroxol with glucocerebroside exerted a synergistic immunoprotective effect in a model of immune-mediated acute liver damage.
Le texte complet de cet article est disponible en PDF.Abbreviations : GC, ConA, PMNLs, IL, TNF, DC, NKT, IFN, PBS, AST, ALT, FACS, TGF
Keywords : Ambroxol, immune mediated hepatitis, glucocerebroside
Plan
Vol 132
Article 110890- décembre 2020 Retour au numéro
Article précédent
- New phenalenone analogues with improved activity against Leishmania species
- Atteneri López-Arencibia, Carlos J. Bethencourt-Estrella, Mónica B. Freijo, María Reyes-Batlle, Ines Sifaoui, Desirée San Nicolás-Hernández, Grant McNaughton-Smith, Jacob Lorenzo-Morales, Teresa Abad-Grillo, José E. Piñero
- Evaluation of anti-inflammatory and immunoregulatory activities of Stimunex® and Stimunex D3® in human monocytes/macrophages stimulated with LPS or IL-4/IL-13
- Cristina Aguzzi, Oliviero Marinelli, Laura Zeppa, Giorgio Santoni, Filippo Maggi, Massimo Nabissi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?